McCarthy Cian P, Januzzi James L
Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
Division of Cardiology, Department of Medicine, Massachusetts General Hospital, 32 Fruit Street, Yawkey 5984, Boston, MA 02114, USA; Baim Institute for Clinical Research, Cardiometabolic Trials, 930 Commonwealth Avenue, Boston, MA 02115, USA.
Heart Fail Clin. 2018 Jan;14(1):41-48. doi: 10.1016/j.hfc.2017.08.005.
Suppression of tumorigenicity 2 (ST2) is a member of the interleukin (IL)-1 receptor family, whose role was originally established in the context of inflammatory and autoimmune diseases. More recently, testing for ST2 has been used in the setting of cardiovascular disease. The soluble form of ST2 is a decoy receptor that inhibits beneficial cardioprotective effects of IL-33; such inhibition results in cardiac hypertrophy, myocardial fibrosis, and ventricular dysfunction. Measurement of soluble ST2 has utility for assessing heart failure severity and prognosis. In this review, we examine the role of soluble ST2 in both acute and chronic heart failure.
肿瘤抑制因子2（ST2）是白细胞介素（IL）-1受体家族的一员，其作用最初是在炎症和自身免疫性疾病的背景下确定的。最近，ST2检测已用于心血管疾病的诊断。可溶性ST2是一种诱饵受体，可抑制IL-33的有益心脏保护作用；这种抑制会导致心脏肥大、心肌纤维化和心室功能障碍。可溶性ST2的测量有助于评估心力衰竭的严重程度和预后。在这篇综述中，我们研究了可溶性ST2在急性和慢性心力衰竭中的作用。
